Patrys Overview

  • Founded
  • 2006
Founded
  • Status
  • Public
  • Employees
  • 7
Employees
  • Stock Symbol
  • PAB
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $0.03
  • (As of Friday Closing)

Patrys General Information

Description

Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 and PAT-DX1-NP, and PAT-LM1. Its lead technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody which penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

Contact Information

Website
www.patrys.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
ASX
Primary Office
  • Leydin Freyer
  • Level 4, 100 Albert Road
  • South Melbourne, Victoria 3205
  • Australia
+61 (03) 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Patrys Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.03 $0.03 $56M 1.83B 12.8M

Patrys Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019
EV 68,184 68,184 6,098 18,730
Revenue 18 20
EBITDA (1,849) (339)
Net Income (1,841) (294)
Total Assets 3,694 5,556
Total Debt 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Patrys Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Patrys‘s full profile, request access.

Request a free trial

Patrys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company
Drug Discovery
South Melbourne, Australia
7 As of 2014
000.00
000000000 000.00

00000000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
0000000000000
Oslo, Norway
00 As of 0000
000.00
000000000 000.00

00000000

rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat c
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Patrys Competitors (57)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Targovax Formerly VC-backed Oslo, Norway 00 000.00 000000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
0000000 000000 Formerly VC-backed New York, NY 000 00000 00000000 00000
0000000 Venture Capital-Backed Houston, TX 00 000.00 000000000 - 000.00
You’re viewing 5 of 57 competitors. Get the full list »

Patrys Executive Team (7)

Name Title Board Seat Contact Info
James Campbell Ph.D Chief Executive Officer & Managing Director
Deanne Greenwood Ph.D Vice President, Business Development & Intellectual Property
Valentina Dubljevic Vice President, Scientific & Clinical Development
You’re viewing 3 of 7 executive team members. Get the full list »

Patrys Board Members (5)

Name Representing Role Since
John Read Self Chairman 000 0000
Michael Stork Self Non Executive Director 000 0000
Suzy Jones Patrys Member of Board of Directors 000 0000
You’re viewing 3 of 5 board members. Get the full list »

Patrys Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Patrys Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Patrys‘s full profile, request access.

Request a free trial

Patrys Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 29-Mar-2016 000000000000000000 00000 Biotechnology
0000 0000000000 (0 29-Mar-2016 000000000 00000 00 00000 Buildings and Property
Acceptys 27-Oct-2008 Merger/Acquisition Other Healthcare
To view Patrys’s complete investments and acquisitions history, request access »